Overview:
Tissue Engineering is the study of the growth of new connective tissues, or organs, from cells and a collagenous scaffold to produce a fully functional organ for implantation back into the donor host. This technique allows the organs to be grown from implantation and hence is free from immunological rejection. Tissue engineering is primarily used for the treatment of burns and accident wounds, for cosmetic surgeries, in correcting birth defects, wound care, orthopedics, and in neurology, amongst others. Advancements in the cell culture technology, has encouraged the adaptation of tissue engineering in the healthcare application. Moreover, the use of animal testing models has raised various ethical issues and hence, the demand for tissue engineered human equivalents is growing at a rapid rate.
Tissue engineering market is expected to witness rapid growth due to the rapid diversification and growth as it allows circumvention of the problem of organ shortage. Furthermore, the development in the biochemistry, biomaterials, molecular medicine, genetics, nanotechnology, and biomedical engineering would further assist the market during the forecast period of 2016-2022. According to market experts, the increasing applications of tissue engineering in neurological and dental segments would add up to the growth of the tissue engineering market in future. Favorable policies of the governments in relation to the tissue engineering will also add incremental opportunity to exploit this market.
The global Tissue Engineering Market is segmented on the following bases:
Key Players Identified for Tissue Engineering Market Include:
Medtronic plc, Acell, Inc., Zimmer Biomet, Athersys, Inc., Organogenesis, Inc., Stryker Corporation, ReproCell, Inc.
This report offers:
